Scientific Core 1:Human Clinical and Protein Engineering Core

科学核心1（SC 1）。项目总结/摘要 项目中的三个项目中的每一个都需要纯化的天然和氧化改性 脂蛋白，获得具有已知临床随访的人类临床材料以及天然、突变或 位点特异性后修饰的感兴趣的蛋白质用于他们的研究。人体临床 材料和蛋白质工程核心（科学核心1; SC 1）将提供所有这些服务，允许 扩大本项目各项目拟开展研究的范围、规模和临床意义。 人类临床材料和蛋白质工程核心有3个主要目标：首先，核心将促进 通过提供以下服务，为项目研究者进行人类临床和转化研究：（i） 协调所有IRB文书工作、志愿者的广告/知情同意、患者与特定 表型（例如高LP（a）水平）和抽血服务。(ii)使用标准化SOP进行分离和 以下人体生物材料的表征：全血（例如用于PMN和MPO分离）; 血浆;血清;分离的脂蛋白（例如VLDL、LDL、HDL和LP（a））。(iii)单核细胞分离的协调 通过淘洗。(iv)协调对来自国家实验室的存档人类临床标本（血浆、血清、DNA）的访问 用于拟定临床研究的GeneBank队列。(v)获取人类临床标本， 心血管诊断和预防中心。第二，核心将协助计划调查人员， 通过提供以下服务来进行蛋白质工程和抗体生成：（i）协助研究者 设计、表达和纯化不同种类的野生型和突变形式的蛋白质。(ii)一代 用于体内研究的低内毒素重组蛋白。(iii)使用tRNA的正交氨基酸掺入 突变体特异性地形成携带非天然氨基酸（例如硝基酪氨酸， 氯酪氨酸，Nε-乙酰基-赖氨酸）。和（iv）帮助产生多克隆和单克隆 抗体的最后，核心将作为项目调查人员的教育和培训中心， 学生和研究员。将这些方面的工作和培训集中起来将大大提高其重要性， 创新性和临床相关性的研究在本计划的每个项目中进行。

Scientific Core 1(SC1). Project Summary/Abstract Each of the three Projects within the Program Project will require purified native and oxidatively modified lipoproteins, access to human clinical material with known clinical follow-up and a source of native, mutant or site-specific post-translationally modified proteins of interest to use in their studies. The Human Clinical Material & Protein Engineering Core (Scientific Core 1; SC1) will provide all of these services, allowing for expansion of the scope, scale and clinical significance of proposed studies in each Project of this Program. The Human Clinical Material & Protein Engineering Core has 3 primary objectives: First, the core will facilitate human clinical and translational studies of Program investigators by providing the following services: (i) Coordination of all IRB paperwork, advertising / consenting of volunteers, contact of patients with specific phenotypes (e.g. high LP(a) levels), and phlebotomy services. (ii) Using standardized SOP for isolation and characterization of the following human biological materials: whole blood (e.g. for PMN and MPO isolation); plasma; serum; isolated lipoproteins (e.g. VLDL, LDL, HDL and LP(a)). (iii) Coordination of monocyte isolation via elutriation. (iv) Coordination of access to archival human clinical specimens (plasma, serum, DNA) from the GeneBank cohort for proposed clinical studies. (v) Access to human clinical specimens available within the Center for Cardiovascular Diagnostics & Prevention. Second, the core will assist Program investigators with protein engineering and antibody generation by providing the following services: (i) assist investigators with design, expression, and purification of distinct classes of wild type and mutant forms of proteins. (ii) Generation of low endotoxin recombinant proteins for in vivo studies. (iii) Orthogonal amino acid incorporation using tRNA mutants to specifically form individual recombinant proteins harboring unnatural amino acids (e.g. nitrotyrosine, chlorotyrosine, Nε-acetyl-lysine). And (iv) assistance in generation of both polyclonal and monoclonal antibodies. Finally, the core will serve as an educational and training hub for Program investigators, especially students and fellows. Centralizing these aspects of the work and training will greatly enhance the significance, innovation, and clinical relevance of studies performed in each Project of this Program.